Oligonucleotides targeting rna binding protein sites
AssigneeHoffmann-La Roche Inc.
InventorsJessica Marine Aurore BASTIEN, Katarzyna CHYZYNSKA, Lars JOENSON, Meiling LI, Bettina NORDBO, Jonas VIKESAA
Life of this patent
Estimating the term…
Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsJessica Marine Aurore BASTIEN, Katarzyna CHYZYNSKA, Lars JOENSON, Meiling LI, Bettina NORDBO, Jonas VIKESAA
Estimating the term…
The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells. The contiguous nucleotide sequence of the antisense oligonucleotides comprise 2′-O-methoxyethyl-RNA (2′-MOE) nucleosides and the antisense oligonucleotides are attached to cholesterol moieties.
An antisense oligonucleotide of 8 to 40 nucleotides in length, which comprises a contiguous nucleotide sequence of at least 8 nucleotides in length which is complementary to a sequence comprising (5′-3′) (UG) n, (GU) n, wherein n is 4-20, UGUGUGUG, UGUGUGUGU, UGUGUGUGUG (SEQ ID NO 95), UGUGUGUGUGU (SEQ ID NO 84), UGUGUGUGUGUG (SEQ ID NO 85), UGUGUGUGUGUGU (SEQ ID NO 86), GUGUGUGU, GUGUGUGUG, GUGUGUGUGU (SEQ ID NO 87), GUGUGUGUGUG (SEQ ID NO 88), GUGUGUGUGUGU (SEQ ID NO 89), GUGUGUGUGUGUG (SEQ ID NO 90), or GUGAAUGA, wherein the contiguous nucleotide sequence comprises one or more 2′-O-methoxyethyl-RNA (2′-MOE) nucleosides and wherein the antisense oligonucleotide is attached to at least one cholesterol moiety.
(canceled)
(canceled)
7-10. (canceled)
(canceled)
16-19. (canceled)
21-22. (canceled)
24-30. (canceled)
(canceled)
36-39. (canceled)
41-42. (canceled)
49-51. (canceled)
Dependencies are inferred from the claim text.